Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19
Status:
Completed
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of
Nirmatrelvir/Ritonavir in the treatment of the Omicron variant of COVID-19. The main question
it aims to answer is: Whether the use of the drug can help patients recover from COVID-19.
Patients in both groups were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time.
oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body
temperature >38.5 ℃. The study group was given Nirmatrelvir 300mg/Ritonavir 100mg orally,
q12h, for 5 days, and the control group not given any antiviral drugs.